33302 桃園市龜山區文化一路259號
長庚大學第一醫學大樓10樓B區
TEL: +886-3-211-8800 ext. 3596
Fax: +886-3-211-8700
Targeting APC/C-CDC20 to Enhance the Effectiveness of Paclitaxel
Cancers have been the leading cause of death in Taiwan and Japan for the past 41 and 43 years, respectively, and currently are responsible for about 1/6th of deaths globally. Our goal is to enhance the effectiveness of paclitaxel, which is FDA approved for the treatment of more than 20 types of adult cancers. The therapeutic index of 10 nM paclitaxel, the clinically relevant amount to work with in lab cultured MDA-MB-231 cell lines, is hypothesized not to involve cell cycle arrest in mitosis, but rather may be derived from the formation of multipolar mitotic spindles that can lead to two different cell death fates after a mother cell with a multipolar spindle executes an aberrant mitosis. First, elevated levels of chromosome mis-segregation on the multipolar spindle may induce necrosis/apoptosis/quiescence in the daughter cells. Second, a lagging chromosome(s) in anaphase on the multipolar spindle of the mother cell may lead to a chromatin bridge(s) in cytokinesis that activate the cyclic GMP–AMP Synthase-Stimulator of Interferon Genes (cGAS-STING) pathway in the daughter cells which may promote type I interferon (IFN) secretion resulting in leukocyte recruitment into solid tumors which execute immunogenic cell death, a pathway that can also be activated during apoptosis and/or necrosis. The efficacy of paclitaxel has been enhanced by combinatorial therapies based on anti-immune checkpoint drugs targeting programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1). Many patients do not respond to paclitaxel treatments before critical limiting doses of paclitaxel are reached, caused by adverse side effects such as neutropenia, mucositis and/or neurotoxicity. Our approach is to specifically target the Anaphase-Promoting Complex/Cyclosome-Cell Division Cycle 20 (APC/C-CDC20) enzyme complex to try and delay anaphase entry without inducing a mitotic cell cycle arrest which may enhance the effectiveness of paclitaxel
Grants
2023-present
Taiwan Experience Education Program (TEEP)
2010-present
Chang Gung Memorial Hospital (CMRP)
2011-2017
Taiwan Ministry of Science and Technology (NMRP)
2011-2016
Taiwan Ministry of Education (EMRP)
2003-2005
Ruth L. Kirschstein National Research Service Award (NRSA)
National Institute of Health
Individual Fellowship, F32 GM067509
Laboratory Director: Dr. Andrew W. Murray
Fall 1996
Sandoz Research Fellowship
Laboratory Director: Dr. David Pellman
Fall 1992
Sigma Xi Grant-in-Aid of Research
Laboratory Director: Dr. L. Andrew Staehelin
Summer 1992
Howard Hughes Medical Institute (HHMI) Bioscience Grant
UROP
Laboratory Director: Dr. L. Andrew Staehelin
Spring 1992
Howard Hughes Medical Institute (HHMI) Bioscience Grant
UROP
Laboratory Director: Dr. L. Andrew Staehelin
Summer 1991
Howard Hughes Medical Institute (HHMI) Bioscience Grant
UROP
Laboratory Director: Dr. J. Richard McIntosh
Courses Taught
Fall semester
英文科學寫作與報告(Introduction to English Scientific Writing and Presentation)
Wednesday 8:00-10:00
專題討論(Seminar)
Monday 1:00-3:00
書報討論(Seminar)
Monday 3:00-5:00
生醫英語期刊專業語法(Biological and Biomedical English Paper Writing Style)
Wednesday 1:00-3:00
Spring semester
細胞生物學(Cell Biology)
Thursday 8:00-10:00
專題討論(Seminar)
Thursday 1:00-3:00
書報討論(Seminar)
Monday 1:00-3:00
生物科技產業專業英文(Biotechnology English)
Wednesday 8:00-10:00
細胞生長與細胞凋亡(Cell Growth and Apoptosis)
Wednesday 10:00-12:00
Publications
Peptide inhibitors of the anaphase promoting-complex that cause sensitivity to microtubule poison.